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Abstract
Purpose—Resistance to platinum chemotherapy remains a significant problem in ovarian
carcinoma. Here, we examined the biological mechanisms and therapeutic potential of targeting a
critical platinum resistance gene, ATP7B, using both in vitro and in vivo models.
Experimental Design—Expression of ATP7A and ATP7B was examined in ovarian cancer cell
lines by real-time reverse transcription-PCR and Western blot analysis. ATP7A and ATP7B gene
silencing was achieved with targeted small interfering RNA (siRNA) and its effects on cell viability
and DNA adduct formation were examined. For in vivo therapy experiments, siRNA was
incorporated into the neutral nanoliposome 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC).
Results—ATP7A and ATP7B genes were expressed at higher levels in platinum-resistant cells
compared with sensitive cells; however, only differences in ATP7B reached statistical significance.
ATP7A gene silencing had no significant effect on the sensitivity of resistant cells to cisplatin, but
ATP7B silencing resulted in 2.5-fold reduction of cisplatin IC50 levels and increased DNA adduct
formation in cisplatin-resistant cells (A2780-CP20 and RMG2). Cisplatin was found to bind to the
NH2-terminal copper-binding domain of ATP7B, which might be a contributing factor to cisplatin
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resistance. For in vivo therapy experiments, ATP7B siRNA was incorporated into DOPC and was
highly effective in reducing tumor growth in combination with cisplatin (70-88% reduction in both
models compared with controls). This reduction in tumor growth was accompanied by reduced
proliferation, increased tumor cell apoptosis, and reduced angiogenesis.
Conclusion—These data provide a new understanding of cisplatin resistance in cancer cells and
may have implications for therapeutic reversal of drug resistance.
Ovarian cancer has the highest mortality rate among all gynecologic malignancies (1).
Following cytoreductive surgery, treatment with paclitaxel and platinum has become a
recommended approach for initial chemotherapy (2). Current combination chemotherapy
regimens produce complete remission in up to 80% of patients with advanced ovarian cancer.
However, despite these initial high response rates, most patients suffer relapse and require
treatment with multiple subsequent chemotherapy regimens (3). Successful management of
advanced or recurrent gynecologic malignancies is often difficult due to both intrinsic and
acquired resistance of cancer cells to chemotherapeutic agents (4–6). Therefore, novel
strategies for overcoming resistance are needed.
Translational Relevance
Resistance to platinum chemotherapy remains a significant problem in ovarian carcinoma.
Although several potential targets have been identified, an understanding of the underlying
mechanisms and practical approaches for reversing resistance has been largely lacking.
Here, we used a highly efficient method of systemic small interfering RNA delivery using
neutral nanoliposomes to target a key gene involved in cisplatin resistance and provide novel
insights into its mechanism of action. These findings offer new opportunities for
development of molecular therapies to reverse chemotherapy resistance.
Cisplatin exerts its cytotoxicity by forming platinum-DNA adducts that arrest the cell in G1,
S, or G2-M phases of the cell cycle, which ultimately lead to programmed cell death. Enhanced
DNA repair, increased intracellular levels of glutathione or metallothionein, and drug
accumulation may lead to resistance of cells to cisplatin (7–11). In addition, decreased influx
or increased efflux of cisplatin may contribute to resistance. However, the mechanisms
underlying these drug accumulation defects are poorly understood. Recent studies suggest that
the transporter that mediates copper uptake and efflux may also regulate the cellular
pharmacology of cisplatin (12,13). Specifically, two copper transporters, ATP7A and ATP7B,
are expressed at higher levels in platinum-resistant cell lines (14–17) and have been
functionally implicated in resistance to several platinum agents, including cisplatin,
carboplatin, and oxaliplatin (17). ATP7B was also shown to be overexpressed in several solid
tumors, including gastric, breast, esophageal, hepatocellular, colorectal, uterine, and oral
squamous cell carcinomas (18–24). ATP7A and ATP7B are members of the P-type ATPase
family of transporters and are the product of genes affected in two disorders of copper
homeostasis in humans, Menkes disease and Wilson's disease, respectively (25,26). The
primary function of ATP7A and ATP7B is to transport copper into the lumen of the trans-
Golgi network (TGN) for the biosynthesis of copper-dependent enzymes and to facilitate export
of excess copper from the cell by sequestering copper into exocytic vesicles (27). Cu-ATPases
bind copper at their large NH2-terminal domain and then transfer copper across the membrane
using the energy of ATP hydrolysis; elevated copper stimulates the Cu-ATPase activity and
causes intracellular trafficking of these transporters from the TGN to exocytic vesicles.
To date, the ability to target chemotherapy resistance genes has been limited. We have recently
developed highly efficient methods for in vivo gene silencing using small interfering RNA
(siRNA) incorporated into neutral nanoliposomes, 1,2-dioleoyl-sn-glycero-3-
Mangala et al. Page 2
Clin Cancer Res. Author manuscript; available in PMC 2010 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
phosphatidylcholine (DOPC; refs. 28, 29). Here, we used this technology to silence key
cisplatin resistance genes and show antitumor efficacy with ATP7B gene silencing.
Materials and Methods
Cell lines and culture
The derivation, source, and propagation of human epithelial ovarian cancer cell lines, such as
cisplatin-sensitive (A2780-PAR) and platinum-resistant (A2780-CP20 and RMG2) epithelial
ovarian cancer cell lines, were maintained as previously described (30). The A2780-CP20 cell
line was developed by sequential exposure of the A2780 cell line to increasing concentrations
of cisplatin. All experiments were done with 70% to 80% confluent cultures.
ATP7A and ATP7B gene silencing by siRNA
siRNA constructs targeted to ATP7A and ATP7B were designed and purchased from Qiagen.
The target sequences were 5′-CTGGACCGGATTGTTAATTAT-3′ (for ATP7A) and 5′-
CCAATTGATATTGAGCGGTTA-3′ (for ATP7B). In vitro transient transfection was done
as described previously (28). Briefly, cells were transfected with ATP7A- and/or ATP7B-
specific or scrambled (control) siRNA using RNAiFect reagent (Qiagen). At selected time
intervals, cells were harvested to measure mRNA and protein levels of ATP7B using reverse
transcription-PCR and Western blot analysis, respectively. An oligonucleotide sequence that
did not have homology to any human mRNA (scrambled siRNA as determined by a National
Center for Biotechnology Information BLAST search) served as a control.
Reverse transcription-PCR
Total RNA was isolated by using Qiagen RNeasy kit. cDNA was synthesized by using the
SuperScript First-Strand kit (Invitrogen) as per the manufacturer's instructions. cDNA was
subjected to PCR using specific primers 5′-CTGGCAAGGCAGAAGTAAGG-3′ (sense) and
5′-TGCAAAGTGGTGGTCCATAA-3′ (antisense) for ATP7A and 5′-
GGTGTTCTCTCCGTGTTGGT-3′ (sense) and 5′-GGCTGCACAGGAAAGACTTC-3′
(antisense) for ATP7B; β-actin was used as a housekeeping gene. PCR was done with 5 to 25
μg of reverse-transcribed RNA and 100 ng/μL of sense and antisense primers in a total volume
of 20 μL. Each cycle consisted of 45 s of denaturation at 94°C, 1 min of annealing at 55°C,
and 45 s of elongation at 72°C (22 cycles). Amplified PCR products were analyzed by
electrophoresis on 1% agarose gel with Tris-borate-EDTA buffer and visualized under UV
light after staining with ethidium bromide.
Western blot analysis
Cells grown to 80% confluence were harvested and lysed in modified
radioimmunoprecipitation assay buffer (50 mmol/L Tris, 150 mmol/L NaCl, 1% Triton X-100,
0.5% deoxycholate, 25 μg/mL leupeptin, 10 μg/mL aprotinin, 2 mmol/L EDTA, 1 mmol/L
sodium orthovanadate) as previously described (29). To prepare lysate from snap-frozen tissue
of in vivo tumors, ∼30 mm3 slices of tissue were homogenized in modified
radioimmunoprecipitation assay buffer and the lysates were centrifuged at 12,500 rpm for 20
min at 4°C. Total protein concentration of the supernatant was determined using the
bicinchoninic acid protein assay reagent kit (Pierce). Protein (30-50 μg) was separated by SDS-
PAGE on a 6% gel and electrophoretically transferred onto a nitrocellulose membrane. The
blots were blocked for 1 h in 5% milk powder in TBST [10 mmol/L Tris (pH 8), 150 mmol/L
NaCl, 0.05% Tween 20] and incubated at 4°C overnight with anti-ATP7A and anti-ATP7B
antibodies (Novus Biologicals) at dilutions of 1:1,000 and 1:500, respectively. ATP7B
antibody recognized a band at 165 kDa, representing ATP7B protein, and also recognized an
unknown band at ∼195 kDa. After being washed in TBST, blots were probed with horseradish
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peroxidase–conjugated goat anti-rabbit antibodies (GE Healthcare) in TBST for 1 h at room
temperature. Immunoreactive proteins were visualized using enhanced chemiluminescence
(Perkin-Elmer). All membranes were stripped and reprobed with an anti–β-actin antibody
(Sigma-Aldrich) at a dilution of 1:2,000 to ensure even loading of proteins.
Cytotoxicity [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay
The cytotoxicity of both sensitive and resistant cells to cisplatin was determined by measuring
their ability to reduce the tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] to a formazan, as
described previously (31). Briefly, A2780-PAR and A2780-CP20 cells were plated at 2 ×
103 per well in 96-well plate and allowed to adhere overnight. Cells were transfected with
control or ATP7A- and/or ATP7B-targeted siRNAs. After 48 h of transfection, the cells were
exposed to increasing concentrations of CDDP (cis-diamminedichloroplatinum or cisplatin;
final concentration range, 0.01-32 μmol/L; LKT Laboratories). After 72 h of cisplatin exposure,
cells were incubated with 0.15% 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) for 2 h at 37°C. The supernatant was removed and cells were dissolved in 100
μL DMSO. The absorbance at 570 nm was recorded, and the IC50 was determined.
Immunocytochemistry of ATP7B
Tumor cells (80-90% confluent) were grown on coverslips (1:20 dilution) for 24 to 48 h at 37°
C and treated with 50 μmol/L bathocuproinedisulfonic acid disodium salt (BCS) to decrease
copper levels and then treated with CuCl2 or CDDP (2 or 10 μmol/L) at 37°C for 1 h. Cells
were fixed by immersing in acetone for 30 s at −20°C and then blocked overnight at 4°C in a
blocking buffer containing 1% gelatin/1% bovine serum albumin in PBS. Cells were incubated
with a primary antibody raised against the NH2-terminal domain of ATP7B and syntaxin-6
(TGN marker) at room temperature for 1 h (each antibody at a 1:500 dilution). After being
washed thrice with PBS for 30 min, cells were incubated for 1 h with fluorescently labeled
secondary antibodies (Alexa Fluor 488 donkey anti-rat for ATP7B and Alexa Fluor 555 donkey
anti-mouse for syntaxin-6; Molecular Probes, Invitrogen). Cells were washed again with PBS
as described above and then mounted using mounting medium containing 4′,6-diamidino-2-
phenylindole (Vector Laboratories). Images were analyzed using 100× with a Zeiss confocal
scanning microscope (Carl Zeiss); colocalization of ATP7B and syntaxin was evaluated using
multiple images and Zeiss software package (track option).
DNA adduct formation assay
Eighty percent of confluent cells were incubated with cisplatin at concentrations up to 20
μmol/L at 37°C for 4 h. Cells were centrifuged at 1,000 rpm for 5 min and washed twice with
ice-cold PBS. Cell pellets were digested overnight at 55°C with 1 mol/L benzethonium
hydroxide (0.075 mL). Samples were then acidified with 0.1 mL of 1 N HCl and the platinum
content was determined in a flame atomic absorption spectrometer (SpectrAA300, Varian). To
determine protein content, cell pellets from parallel incubations were first lysed with lysis
buffer and then the protein content was determined by bicinchoninic acid method. The
experiment was repeated for a total of three times, and the mean value was recorded.
Binding of cisplatin to the NH2-terminal domain of ATP7B (N-ATP7B)
N-ATP7B (previously referred as N-WNDP) was expressed and purified as a fusion protein
with maltose binding protein as previously described (32). Before binding experiments,
purified protein was fully reduced with 100 μmol/L DTT and then dialyzed overnight using
the buffer containing 25 mmol/L phosphate and 150 mmol/L NaCl (pH 7.5). Copper or cisplatin
was added to the N-ATP7B in increasing molar ratios up to 60-fold excess over protein (10-
fold excess over metal-binding sites) for 10 min at room temperature. Next, 7-diethylamino-3-
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(4′-maleimidylphenyl)-4-methylcoumarin (CPM; Invitrogen) was added in the dark for 5 min
(in equimolar concentrations to metal-binding cysteines) and quenched with 20 μmol/L
glutathione. Samples were run on a 12% Laemmli gel, and fluorescent images were taken using
a FluorChem 5500 (Alpha-Innotech Corp.). Gels were then fixed, stained with Coomassie, and
imaged again. The intensity of CPM labeling was normalized to protein levels by densitometry
and expressed as a percentage of protein labeling in the absence of cisplatin. This experiment
was replicated thrice, and the mean value was recorded.
Overexpression of N-ATP7B in A2780-PAR cells
After 24 h of plating, cells were transfected with empty vector pTriEx-cDNA or pTriEx-N-
ATP7B cDNA (ATP7B-WND) using Lipofectamine 2000 (Invitrogen) according to the
manufacturer's protocol. Briefly, cDNA and Lipofectamine solution (1:2.5 ratio) were diluted
with serum-free medium and two solutions were mixed and incubated for 20 min at room
temperature. This mixture was added to cells and serum-free medium was replaced with regular
serum-containing medium after 6 to 8 h of incubation. After 48 h, cells were trypsinized and
plated in 96-well plates. After attachment of cells, cisplatin was added to the cells and incubated
for 72 h at 37°C. Cytotoxicity was determined by MTT assay as described above. The extent
of protein overexpression was also confirmed by Western blot analysis.
Liposomal siRNA preparation
For in vivo delivery, siRNA was incorporated into DOPC as previously described (28). Briefly,
siRNA and DOPC were mixed at a ratio of 1:10 (w/w) siRNA/DOPC in excess tertiary butanol.
Tween 20 was added to the mixture at the ratio of 1:19 (Tween 20:siRNA/DOPC). After
vortexing, the mixture was frozen in an acetone/dry ice bath and lyophilized. Before in vivo
administration, this mixture was hydrated with 0.9% saline to a concentration of 25 μg/mL and
200 μL of mixture were used per injection.
Orthotopic model of ovarian cancer and tissue processing
Female athymic nude mice (NCr-nu) were purchased from the National Cancer Institute-
Frederick Cancer Research and Development Center (Frederick, MD). All mice were housed
and maintained under specific pathogen-free conditions in facilities approved by the American
Association for Accreditation of Laboratory Animal Care and in accordance with current
regulations and standards of the U.S. Department of Agriculture, U.S. Department of Health
and Human Services, and NIH. All studies were approved and supervised by the University of
Texas M. D. Anderson Cancer Center Institutional Animal Care and Use Committee. All mice
were used in these experiments when they were 8 to 12 wk old.
Before injection, tumor cells were washed twice with PBS, detached by 0.1% cold EDTA,
centrifuged for 7 min, and reconstituted in HBSS (Invitrogen). Cell viability was confirmed
by trypan blue exclusion. Tumors were established by i.p. injection of either 1.0 × 106 A2780-
CP20 or 3.0 × 106 RMG2 cells. Once established, this tumor model reflects the growth pattern
of advanced ovarian cancer (33,34).
Long-term therapy experiments were done using two platinum-resistant ovarian cancer cell
lines: A2780-CP20 and RMG2. To assess the effects of siRNA therapy on tumor growth,
treatment was initiated 1 wk after i.p. injection of tumor cells. Mice were divided into five
groups (n = 10 mice per group): (a) empty liposome (DOPC; vehicle), (b) control siRNA-
DOPC (150 μg/kg i.p. twice weekly), (c) control siRNA-DOPC + cisplatin (160 μg/mouse i.p.
weekly), (d) ATP7B siRNA-DOPC (150 μg/kg i.p. twice weekly), and (e) ATP7B siRNA-
DOPC + cisplatin (doses same as individual treatments). Treatment was continued until control
mice became moribund (typically 4-6 wk following tumor cell injection). At the time of
sacrifice, mouse weight, tumor weight, number of nodules, and distribution of tumors were
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recorded. Tissue samples were snap frozen for lysate preparation or fixed in formalin for
paraffin embedding. The individuals who did the necropsies, tumor collections, and tissue
processing were blinded to the treatment group assignments.
Immunohistochemistry
Proliferating cell nuclear antigen (PCNA), terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling (TUNEL) staining, and microvessel density (MVD) were done using
formalin-fixed, paraffin-embedded tumor sections (8 μm thickness) as previously described
(35). Briefly, after deparaffinization and rehydration, antigen retrieval was done using citrate
buffer (0.1 mol/L; pH 6.0) in a microwave. Endogenous peroxidase and nonspecific epitopes
were blocked with 3% H2O2/methanol for 12 min and 5% normal horse serum and 1% normal
goat serum for 20 min. Sections were incubated with primary anti-PCNA (PC-10, mouse IgG;
Dako Corp.) or anti-CD31 (Pharmingen) overnight at 4°C and secondary horseradish
peroxidase–conjugated antibody (Serotec Bioproducts) for 1 h at room temperature.
Horseradish peroxidase was detected with 3,3′-diaminobenzidine (Phoenix Biotechnologies)
substrate for 5 min, washed, and counterstained with Gill's no.3 hematoxylin (Sigma-Aldrich)
for 15 s and mounted.
To quantify apoptosis, we did TUNEL staining on 8-μm-thick paraffin-embedded tumor slides
as previously described (35). Briefly, after deparaffinization, slides were treated with
proteinase K (1:500) and a positive control slide was treated with DNase. Endogenous
peroxidase activity was blocked with 3% H2O2 in methanol. After being rinsed with TdT buffer
(30 mmol/L Trizma, 140 mmol/L sodium cacodylate, 1 mmol/L cobalt chloride), slides were
incubated with terminal transferase (1:400; Roche Diagnostics) and biotin-16-dUTP (1:200;
Roche Diagnostics) and blocked with 2% bovine serum albumin. Slides were then incubated
with peroxidase streptavidin (1:400) at 37°C for 40 min, visualized with 3,3′-diaminobenzidine
chromogen, and counterstained with Gill's hematoxylin. The apoptotic and proliferative indices
and MVD were determined by the number of positive cells in five randomly selected high-
power fields exclusive of necrotic areas. To quantify PCNA expression, MVD, and apoptotic
cells, the number of positive cells (3,3′-diaminobenzidine staining) was counted in 10 random
0.159 mm2 fields at ×100 magnification. All staining was quantified by two investigators in a
blinded fashion (35).
ELISA
To examine the levels of vascular endothelial growth factor (VEGF) in ATP7B-silenced
tumors, we did ELISA using the VEGF Quantikine kit from R&D Diagnostics according to
the manufacturer's instructions. The experiment was done twice.
Statistics
For animal experiments, 10 mice were assigned per treatment group. To judge the necessary
sample size for proposed experiments, we considered a two-way ANOVA model. For an effect
size (ratio of fixed effect and residual SD) of 1.3, this sample size will be sufficient to provide
80% power for a test at significance level of 0.05. Mouse and tumor weights and the number
of tumor nodules for each group were compared using Student's t test (for comparisons of two
groups). Statistical analyses were done using Statistical Package for the Social Sciences 12.0
for Windows (SPSS, Inc.). A two-tailed P ≤ 0.05 was deemed statistically significant.
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Results
In vitro effects of ATP7A and ATP7B silencing
Before initiating in vivo experiments, we first identified the cisplatin IC50 levels for multiple
ovarian cancer cell lines (Supplementary Table S1). The A2780-CP20, IGROV-CP20, and
RMG2 cell lines are resistant to cisplatin with IC50 levels of ≥12 μmol/L. Next, we examined
expression of ATP7A and ATP7B in the ovarian cancer cell lines using quantitative real-time
reverse transcription-PCR. Although levels of both genes were higher in the cisplatin-resistant
cells, only ATP7B reached statistical significance (Supplementary Fig. S1A). Both ATP7A
and ATP7B were previously implicated in resistance to cisplatin (16, 17). Consequently, to
determine which of these transporters contributes to drug resistance, we used siRNA targeted
against ATP7A or ATP7B. Transfection of A2780-CP20 cells with the targeted siRNAs
resulted in decreased protein levels by 73% (ATP7A) and 68% (ATP7B) at 48 hours (Fig. 1A).
Similarly, mRNA expression was decreased for both genes at 48 hours (Supplementary Fig.
S1B and C). Next, the effects of ATP7A or ATP7B silencing were assessed on tumor cell
sensitivity to cisplatin using the MTT assay. ATP7A gene silencing had no significant effect
on sensitivity to cisplatin in either cell line (Fig. 1B). In contrast, ATP7B gene silencing
increased sensitivity to cisplatin by 5.5-fold (P < 0.01) in the A2780-PAR cells (Fig. 1B) and
2.5-fold (P < 0.05) in the A2780-CP20 cells (Fig. 1B). The combination of ATP7A and ATP7B
gene silencing showed effects similar to ATP7B siRNA alone, suggesting that ATP7A down-
regulation did not contribute significantly to sensitization of the resistant A2780-CP20 cells
to cisplatin. Therefore, for all subsequent studies, we focused on the contribution of ATP7B
to platinum resistance using in vivo orthotopic mouse models of ovarian cancer. ATP7A and
ATP7B siRNA sequences did not show cross-reactivity against each other (data not shown).
Trypan blue dye assay confirmed that transfection of cells with siRNAs did not affect cell
viability after 48 hours of transfection (Supplementary Fig. S1D), suggesting that siRNA was
not toxic to cells.
Cisplatin does not alter intracellular localization of ATP7B
To better understand the mechanisms by which copper-transporting ATPases mediate cisplatin
resistance, we examined the effect of cisplatin on ATP7B in A2780-CP20 cells in more detail.
In hepatic cells, the efflux of copper by ATP7B is associated with the trafficking of ATP7B
from the TGN to vesicles (36). Consequently, we asked whether cisplatin induces ATP7B
trafficking from the TGN, a step that precedes metal efflux. To better visualize the potential
effect of cisplatin and avoid metal competition, cells were first depleted of copper with the
copper chelator BCS and then treated with cisplatin (Fig. 2). As expected, in copper-depleted
cells, ATP7B was found in the perinuclear compartment where it colocalized with the TGN
marker syntaxin-6. Treatment with cisplatin or copper (either 2 or 10 μmol/L) did not produce
a noticeable change in the ATP7B pattern (Fig. 2A). ATP7B remained colocalized with
syntaxin-6 and remained in a perinuclear location, suggesting that ATP7B largely colocalized
with the TGN marker under all experimental conditions.
To verify the lack of ATP7B trafficking in response to cisplatin in A2780-CP20 cells, we
evaluated colocalization between ATP7B and syntaxin using multiple images and Zeiss
software package. Trafficking in response to copper in HepG2 was used as a positive control
(Fig. 2B). Following treatment with BCS, ATP7B showed colocalization with the TGN marker
in both cell types. This colocalization was lost in the HepG2 cells in response to copper
elevation, indicative of trafficking. However, there was no significant change in the
colocalization of ATP7B and the TGN marker in the A2780-CP20 cells (Fig. 2B).
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ATP7B silencing increases DNA adduct formation
Although ATP7B does not show noticeable trafficking, it may increase cell resistance to
cisplatin either through a slow sequestration of drug in the TGN or by binding cisplatin at its
metal-binding sites and rendering the drug unavailable. In either case, down-regulation of
ATP7B would be expected to increase the intracellular concentration of “active” cisplatin. To
determine the effects of ATP7B gene silencing, we compared platinum content and DNA
adduct formation in A2780-PAR and A2780-CP20 cells (Fig. 3A). ATP7B gene silencing had
no effect on whole-cell platinum accumulation (data not shown) consistent with the lack of
ATP7B trafficking and metal efflux. However, ATP7B silencing resulted in a 30% increase in
DNA adduct formation in both A2780-PAR and A2780-CP20 cells (P < 0.05 versus untreated
and control siRNA–treated cells; Fig. 3A), suggesting a role for ATP7B in regulating
intracellular distribution of cisplatin.
Cisplatin binds to the NH2-terminal domain of ATP7B
ATP7B has a large NH2-terminal domain (N-ATP7B) that contains six copper-binding sites
(37). In addition, N-ATP7B can bind other metals, such as zinc, although with lower affinity
(38). Therefore, we next examined the ability of N-ATP7B to bind cisplatin. Previously,
binding of copper to recombinant N-ATP7B was shown to protect metal-coordinating cysteine
residues from labeling with the fluorescent CPM (39). Consequently, we tested whether such
protection occurs in the presence of increasing concentrations of cisplatin (Fig. 3B). Incubation
of N-ATP7B with both copper and cisplatin decreased fluorescent labeling, suggesting that
both metals can interact with the metal-binding sites in ATP7B. Such binding to overexpressed
ATP7B may contribute to increased resistance of A2780-CP20 cells to cisplatin. To examine
whether binding of cisplatin to the NH2-terminal domain of ATP7B is sufficient to increase
resistance to cisplatin, we overexpressed the recombinant N-ATP7B in cisplatin-sensitive
A2780-PAR cells and this resulted in a 2-fold increase in resistance (IC50) of the A2780-PAR
cells to cisplatin (P < 0.03; Fig. 3C). When A2780-PAR cells were transfected with an empty
vector (pTriEx), as expected, no ATP7B protein was expressed (A2780-PAR-pTriEx)
compared with A2780-CP20 cells. Overexpression of recombinant N-ATP7B (70 kDa) in the
A2780-PAR cells (A2780-PAR-WND) produced protein levels that were comparable with
those of the full-length ATP7B in A2780-CP20 cells (Fig. 3D) and yielded increased resistance,
suggesting that binding of the NH2-terminal domain is one of the contributing factors to
resistance. We have attempted to isolate the His-tagged N-ATP7B from cells treated with
fluorescent cisplatin to evaluate stoichiometry of cisplatin binding; however, the sensitivity of
our assays was insufficient for such measurements.
In vivo effects of ATP7B inhibition on ovarian carcinoma
The therapeutic potential of ATP7B gene silencing for reversing platinum resistance was tested
in vivo using ATP7B siRNA delivery by DOPC (28). Before therapy experiments, we
established the duration of ATP7B gene silencing following i.p. administration of ATP7B
siRNA in DOPC. Nude mice bearing A2780-CP20 tumors were injected with a single dose of
ATP7B siRNA-DOPC (150 μg/kg), and tumors were harvested after 24, 48, 72, and 96 hours
(Fig. 4A). ATP7B siRNA-DOPC reduced the expression of ATP7B (60%) by 48 hours and
returned to baseline levels at 96 hours. Based on these results, we administered ATP7B siRNA-
DOPC twice weekly for subsequent therapy experiments. To check for nonspecific
inflammatory responses produced by siRNA in vivo, we measured cytokine levels in plasma
2 hours after the i.v. administration of normal saline, empty liposome (DOPC), control siRNA-
DOPC, or ATP7B siRNA-DOPC into mice. There was no significant induction of IFN-γ,
interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-10, and tumor necrosis factor-α in any of the groups
(Supplementary Table S2), suggesting that administration of siRNA did not induce nonspecific
inflammatory responses, which agreed with previous reports (40).
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To simulate treatment of advanced small-volume disease, we initiated therapy 1 week after
tumor cell injection using the A2780-CP20 and RMG2 models (Fig. 4B). Mice were divided
into the following five groups (n = 10 mice per group): (a) empty liposomes, (b) control siRNA-
DOPC, (c) control siRNA-DOPC + cisplatin, (d) ATP7B siRNA-DOPC, and (e) ATP7B
siRNA-DOPC + cisplatin. All of the animals were sacrificed when animals in any group
appeared moribund (3-5 weeks of therapy depending on the cell line). Treatment with ATP7B
siRNA-DOPC alone resulted in 40% to 60% reduction in tumor weight in both models
compared with treatment with either empty liposome or control siRNA-DOPC (P < 0.05;
RMG2 tumors). Combination therapy (ATP7B siRNA-DOPC and cisplatin) resulted in even
greater reduction (70% and 88% in the A2780-CP20 and RMG2 models, respectively; Fig.
4B) in tumor weight than either cisplatin/control siRNA-DOPC or ATP7B siRNA-DOPC alone
(P < 0.05 versus either empty liposome or control siRNA-DOPC for A2780-CP20 and P <
0.001 versus either control siRNA-cisplatin or ATP7B siRNA-DOPC in RMG2 tumors).
To further evaluate the effects of ATP7B therapy on tumor growth inhibition, we analyzed
tumor incidence, tumor weight distribution, and number of nodules. Again, combination
therapy showed the greatest effect with 60% fewer tumor nodules (P < 0.05 versus empty
liposome and control siRNA-DOPC groups) in A2780-CP20 and 75% fewer (P < 0.05 versus
empty liposome and control siRNA-DOPC groups) in RMG2 cells (Table 1; Supplementary
Fig. S2). There was no obvious toxicity noted in the animals during therapy experiments, as
assessed by changes in behavior, feeding habits, and mobility. The mean body weight was also
similar between the treatment groups (data not shown).
Effect of ATP7B silencing on tumor proliferation, apoptosis, and angiogenesis
To explore possible mechanisms underlying the observed inhibition of tumor growth, we
examined the effects of ATP7B silencing on tumor cell proliferation and apoptosis by using
PCNA and TUNEL staining. In the A2780-CP20 tumor model, treatment with ATP7B siRNA-
DOPC alone reduced proliferation by 57% (P < 0.05), and combination therapy further reduced
it by 75% (P < 0.05) compared with the empty liposome and control siRNA-DOPC groups
(Fig. 5A). TUNEL staining showed that combination therapy resulted in a 72% increase in
tumor cell apoptosis (P < 0.001) compared with empty liposome or control siRNA-DOPC
groups and a 52% increase compared with ATP7B siRNA-DOPC alone (Fig. 5B). The RMG2
model had similar effects of therapy on proliferation and apoptosis (data not shown).
Because of growing evidence that copper plays an important role in angiogenesis (41), we
examined MVD in ATP7B siRNA–treated tumors by CD31 staining. ATP7B siRNA-DOPC
alone reduced MVD by 58% (P < 0.05), and combination therapy further reduced MVD by
81% (P < 0.001; Fig. 5C) compared with control groups. Based on the role of copper in
regulating VEGF (42), we also examined tumor copper and VEGF content following ATP7B
silencing. There was a 47% decrease (P < 0.02) in tumor copper content following ATP7B
silencing (data not shown). ATP7B siRNA-DOPC alone reduced VEGF content by 75% (P <
0.05), and combination therapy further reduced it by 89% compared with the empty liposome–
treated tumors (P < 0.001; Fig. 5D).
Discussion
We show here that in vitro ATP7B gene silencing leads to increased sensitivity to cisplatin in
both parental and cisplatin-resistant cell lines. ATP7B gene silencing using a highly efficient
method for systemic siRNA delivery resulted in antitumor efficacy in a platinum-resistant
model of ovarian cancer in mice. Addition of cisplatin to ATP7B siRNA-DOPC, but not control
siRNA-DOPC, further reduced the tumor burden in these mice, indicating that the effects were
not due to nonspecific siRNA toxicity. These findings may be explained based on a benefit
resulting from the coadministration of both drugs working independently of each other and not
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necessarily in vivo sensitization. The antitumor activity was accomplished through decreased
tumor cell proliferation and MVD and increased apoptosis. To the best of our knowledge, this
study provides the first in vivo evidence about the therapeutic efficacy of targeting ATP7B in
combination with cisplatin in platinum-resistant ovarian cancer.
Given the central role of platinum-based chemotherapy in the treatment of many cancers,
including ovarian cancer, strategies to circumvent inherent or acquired resistance are highly
desirable. Death of tumor cells in response to chemotherapy is dependent on several factors,
including the amount of drug that enters the cell and the nucleus, amount of DNA adduct
formation, cell tolerability to DNA adducts, and the ability to repair DNA damage (43,44).
Previously, Nakayama and associates (21,45) observed that the levels of ATP7B inversely
correlated with cisplatin sensitivity in nine gynecologic cancer cell lines and that ovarian cancer
patients with ATP7B expression had significantly poorer response to cisplatin-based
chemotherapy than patients lacking detectable ATP7B expression. The contribution of ATP7B
to cisplatin resistance is evident from the results of ATP7B down-regulation. Reduced
expression of ATP7B achieved by siRNA knockdown resulted in a 2.5-fold enhancement of
sensitivity of these cells to cisplatin. Significantly, the down-regulation of another Cu-ATPase
ATP7A had no effect, emphasizing the important and specific role of ATP7B in resistance of
A2780-CP20 cells to cisplatin.
The different effects of ATP7A and ATP7B silencing on cisplatin resistance may be linked to
their different levels of expression and/or their distinct trafficking properties. In A2780-CP20
cells, ATP7A traffics toward the plasma membrane in response to copper elevation (data not
shown), presumably to export excess metal out of the cell. In contrast, ATP7B shows no
relocalization in response to either copper or cisplatin and is likely to sequester metals in the
intracellular compartments. If in A2780-CP20 cells the ATP7A-mediated export of cisplatin
is much slower than cisplatin uptake, then ATP7A inactivation would not have a significant
effect on cisplatin resistance. In contrast, the concept that ATP7B controls intracellular
distribution of cisplatin is supported by our observation that down-regulation of ATP7B does
not significantly alter the cellular content of cisplatin, and yet, a 30% increase in DNA adduct
formation is observed. This result reflects the increased nuclear availability of cisplatin in
response to ATP7B down-regulation. Therefore, the major mechanism through which
overexpression of ATP7B increases resistance to cisplatin seems to involve blockade of drug
access to the nucleus. This may be due either to ATP7B pumping cisplatin into the lumen of
the TGN or to simple binding of the drug by multiple metal-binding sites in the NH2-terminal
domain (N-ATP7B) of the transporter or both. The latter possibility is supported by our finding
that the recombinant N-ATP7B alone increased cell resistance to cisplatin. While this work
was in preparation, new in vitro data (showing that cisplatin stimulates the catalytic activity of
ATP7B and that this stimulation requires the NH2-terminal region) by Leonhardt and
colleagues (46) provided additional evidence for the role of the NH2-terminal metal-binding
domain in functional interactions between cisplatin and ATP7B.
Despite efficient down-regulation of ATP7B in A2780-CP20 cells, reversal of the resistant
phenotype was not complete, indicating possible involvement of other components of cellular
copper handling machinery (such as high-affinity copper transporter hCTR1,
metallochaperones, and ATP7B regulator COMMD1; ref. 47). Furthermore, changes in
expression of Cu-ATPases alter the intracellular copper balance (17) and this in turn induces
changes in the cell transcriptome (48). However, these additional mechanisms do not diminish
the major contribution of ATP7B. The in vivo therapy with combination of ATP7B siRNA-
DOPC and cisplatin significantly reduced tumor burden, decreased cell proliferation and MVD,
and increased apoptosis, suggesting that this approach might be useful in patients with
platinum-resistant ovarian carcinoma. Copper plays an important role in angiogenesis and it
might be a required cofactor of VEGF-mediated angiogenesis (42). Copper stimulates the
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proliferation and migration of endothelial cells and is required for the secretion of several
angiogenic factors by tumor cells. Copper may bind to angiogenic growth factors or regulate
the production of angiogenic growth factors such as VEGF (42). Thus, therapy aimed at
depleting copper levels through silencing the transporters may have an additional benefit by
reducing angiogenesis. In summary, our data indicate that ATP7B-targeted therapy may
represent a novel therapeutic approach for platinum-resistant human ovarian cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
A, Western blot analysis of ATP7A and ATP7B in A2780-CP20 cells following treatment with
targeted and control siRNA for 24, 48, and 72 h. β-Actin was used as loading control. Protein
levels were quantified by densitometry and expression is shown as arbitrary units. B, effect of
ATP7A and ATP7B silencing on cisplatin sensitivity in ovarian cancer cell lines. A2780-PAR
and A2780-CP20 cells were transfected with ATP7A or ATP7B or control siRNA. After 24
h, cells were treated with cisplatin (0.01-32 μmol/L). Following 72 h of cisplatin exposure,
MTT assay was done to determine the effects on cell viability. Columns, mean values for the
IC50 of three independent experiments; bars, SE. *, P < 0.05; **, P < 0.01, compared with
cisplatin alone.
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Fig. 2.
Effect of cisplatin on intracellular localization of ATP7B. A, A2780-CP20 cells were
immunostained with the anti-ATP7B and anti–syntaxin-6 antibodies. Overlay images showing
colocalization (white) of ATP7B (green) and syntaxin-6 (pink). B, HepG2 and A2780-CP20
cells were treated with copper chelator BCS (50 μmol/L) to deplete cells of copper and then
either kept in BCS or treated with CuCl2 or cisplatin. To verify the lack of ATP7B trafficking
in response to cisplatin in A2780-CP20 cells, we evaluated colocalization between ATP7B and
syntaxin using multiple images and Zeiss software package. Trafficking in response to copper
in HepG2 was used as a positive control. Arrows indicate direction and length of the
densitometry scan.
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Fig. 3.
Effect of ATP7B gene silencing on DNA adduct formation in A2780-sensitive and A2780-
resistant cells. A, the platinum content was determined using flame atomic absorption
spectrometer after incubating A2780-PAR and A2780-CP20 cells with cisplatin for 4 h
followed by digestion with 1 mol/L benzethonium hydroxide and acidification with 1 N HCl.
Columns, mean values from three independent experiments; bars, SE. *, P < 0.05, compared
with untreated or control siRNA–treated cells. B, cisplatin binds to the NH2-terminal domain
of ATP7B (N-ATP7B). The recombinant NH2-terminal domain of ATP7B was incubated with
increasing concentrations of copper or cisplatin (copper and cisplatin were added to the N-
ATP7B in increasing molar ratios up to 60-fold excess over protein). Metal-coordinating
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cysteines in N-ATP7B were labeled with cysteine-directed probe CPM. Top, copper/cisplatin
protects against labeling with the CPM without affecting total amount of protein; bottom,
fluorescence intensity for average of three replicates, defining 100% as the fluorescence/
protein ratio where no ligand was used before labeling. The densitometry of fluorescent gels
indicates that this protection is partial and hence not all metal-binding sites in the N-ATP7B
bind cisplatin. C, overexpression of N-ATP7B increases cisplatin resistance in platinum-
sensitive cells. A2780-PAR cells were transfected with empty vector pTriEx-cDNA or pTriEx-
N-ATP7B cDNA (WND cDNA) using Lipofectamine 2000. After 48 h, cells were incubated
with cisplatin (2 μmol/L) for 72 h at 37°C, and MTT assay was done to determine the difference
in the IC50 levels. Columns, mean values for the IC50 of three independent experiments; bars,
SE. *, P < 0.03, compared with A2780-PAR cells. D, Western blot analysis of overexpression
of NH2-terminal domain of ATP7B in A2780-PAR cells. Cells were transfected with pTriEx-
cDNA or pTriEx-N-ATP7B cDNA as mentioned above and proteins were separated by SDS
gel electrophoresis. β-Actin was used as loading control.
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Fig. 4.
Effect of ATP7B gene silencing on ovarian carcinoma. A, Western blot of lysates from
orthotopic tumor samples collected at 0, 1, 2, 3, and 4 d after a single administration of ATP7B
siRNA or control siRNA incorporated in DOPC. Protein levels were quantified by
densitometry and expression is shown as arbitrary units. B, therapeutic efficacy of siRNA-
mediated ATP7B down-regulation. Nude mice were injected i.p. with 1.0 × 106 A2780-CP20
or 3.0 × 106 RMG2 cells and randomly allocated to one of the following groups: empty
liposome, control siRNA-DOPC, control siRNA-DOPC + cisplatin, ATP7B siRNA-DOPC,
and ATP7B siRNA-DOPC + cisplatin. Treatments were started 1 wk after tumor cell injection
and siRNA/liposomes were administered twice weekly at a dose of 150 μg/kg body weight.
All of the animals were sacrificed when animals in any group appeared moribund (A2780-
CP20, after 3 wk; RMG2, 5 wk starting therapy) and necropsy was done and mouse weight,
tumor weight, and location were recorded. Statistical analysis for tumor weights was done by
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Student's t test. *, P < 0.05, compared with empty liposome or control siRNA-DOPC; **, P <
0.001, compared with control siRNA-DOPC + cisplatin or ATP7B siRNA-DOPC.
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Fig. 5.
ATP7B gene silencing leads to reduced proliferation, increased apoptosis, and reduced MVD
of A2780-CP20 tumors. Immunohistochemical staining for PCNA (A), TUNEL assay (B), and
MVD (C) was conducted to assess cell proliferation, apoptosis, and MVD in A2780-CP20
tumors collected at completion of ATP7B siRNA-DOPC therapy. Original magnification,
×100. Quantification of effects is shown graphically on the right. Bars, 95% confidence
intervals. Treatment arms were compared by Student's t test. *, P < 0.05; **, P < 0.001,
compared with the empty liposome or control siRNA-DOPC groups. D, ATP7B silencing
decreased VEGF levels in tumors. ELISA of A2780-CP20 tumors harvested at the completion
of ATP7B therapy with or without cisplatin. Experiment was done twice. *, P < 0.05; **, P <
0.001, compared with empty liposome group.
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Table 1
Characteristics of tumors after ATP7B siRNA-DOPC treatment with or without chemotherapy
Cell line Treatment Median no. nodules (range) P (vs control)
A2780-CP20 Empty liposome 22 (4-63)
Control siRNA 24 (15-56) ns
Control siRNA + cisplatin 19 (6-39) ns
ATP7B siRNA 13 (1-37) 0.02
ATP7B siRNA + cisplatin 8 (3-33) 0.05
RMG2 Empty liposome 12 (4-25)
Control siRNA 12 (4-21) ns
Control siRNA + cisplatin 8.5 (2-18) ns
ATP7B siRNA 7 (5-10) 0.02
ATP7B siRNA + cisplatin 2.5 (1-6) 0.05
Abbreviation: ns, not significant.
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